BioMarin Pharmaceutical Inc.’s (BMRN) phase II study of Talazoparib for the treatment of patients with deleterious germline BRCA 1 or BRCA 2 mutations and locally advanced and/or metastatic breast cancer has met the protocol-specified criteria to expand enrollment.